Biophan Technologies, Inc., a developer of next-generation medical technology, presented its proprietary nanotech-based solutions for drug delivery, vascular intervention and other global biomedical market segments at the NanoBioConvergence conference held yesterday in the San Francisco Bay Area.
In the presentation, CEO Michael Weiner highlighted Biophan's nanotechnology-based innovations to address a range of multi-billion-dollar segments of the biomedical marketplace. Among other topics, Mr. Weiner discussed the Company's proprietary technology solutions for active drug delivery, designed to enable new applications in a projected $40 billion market. Also presenting at session was Florian Ludwig, Manager of Research & Technology for Guidant Corp., a leading biomedical manufacturer.
Other Biophan nanotech solutions addressed by Mr. Weiner include such state-of-the-art nanotech product initiatives as the Company's biothermal battery technology designed to generate electricity to power implanted medical devices, and proprietary solutions to make medical devices including vascular stents and vena cava filters fully visible and image-compatible with Magnetic Resonance Imaging (MRI) systems. He also discussed the MYO-VAD(TM), a novel heart pump assist device Biophan is developing with MYOTECH, and its unique potential for drug-delivery and/or cell lines directly to the myocardium. Biophan is
"Biophan has long been a leader in the research and development of nanotechnology-based solutions to tap the huge market potential represented by the convergence of nanotechnology and biotechnology," Mr. Weiner said. "Through our proprietary and patented technologies, Biophan has already demonstrated that nanotechnology is an answer to many long-running needed health care issues, such as the need for artifact-free and accurate MRI imaging of vascular stents and other medical devices.
Biophan is a biomedical development leader with an extensive intellectual property portfolio of 156 U.S. patents, licenses, or applications and 46 international applications.
The Company is focused on commercializing its technology via licensing agreements with large manufacturers. Many of the Company's diverse range of advanced solutions enable implanted medical devices and other medical tools to be used safely and imaged effectively within MRI environments.
